Illumina Hits Back At Carl Icahn’s Grail Deal Claims And His Board Nominations
With less than 2% Illumina stock stake, activist’s claims get company pushback Illumina (NASDAQ:ILMN) is hitting back at activist investor Carl Icahn as the genome sequencing biotech firm disputed his inflamatory claims and rejected his proposed board nominations. Icahn, who owns a 1.4% stake in Illumina, began his latest proxy battle on March 13, criticizing management for pursuing the 2021 Grail deal amidst regulatory scrutiny. Q4 2022 hedge fund letters, conferences and more Find A Qualified Financial AdvisorEach advisor has been vetted by SmartAsset and is held to a fiduciary standard to a...